During a presentation at the annual meeting of the European Association for the ...
The healthcare sector is undergoing rapid changes, with genetic testing leading ...
As scientific investigations in the current year persist in highlighting the PIK...
Another failure has befallen the immuno-oncology wager that Gilead Sciences plac...
After facing obstacles in its Alzheimer’s trials for gantenerumab the previous y...
Viatris Inc. and Ocuphire Pharma, Inc. have received the go-ahead from the U.S. ...
The efficacy of medical treatments often varies with age, and this principle hol...
In accordance with FDA guidance, 60 Degrees Pharmaceuticals has opted to halt th...
A mere six weeks after obtaining FDA approval, Astellas Pharma is already consid...
Investors have raised a concern about Morphic’s eagerly awaited EMERALD-1 trial....
Ionis Pharmaceuticals has achieved a significant milestone in their phase 3 clin...
In a strategic maneuver aimed at streamlining its product portfolio, pharmaceuti...
One year after allying with the shared objective of enhancing health management ...
Recently, AbbVie disclosed positive outcomes from a second phase 3 trial of Boto...
After months of looking into various other possibilities, Fresh Tracks Therapeut...
In May of this year, the FDA issued a full response letter that delayed the laun...
